1127 related articles for article (PubMed ID: 29748028)
21. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial.
Nakashima K; Aoshima M; Ohfuji S; Yamawaki S; Nemoto M; Hasegawa S; Noma S; Misawa M; Hosokawa N; Yaegashi M; Otsuka Y
Hum Vaccin Immunother; 2018; 14(8):1923-1930. PubMed ID: 29561248
[TBL] [Abstract][Full Text] [Related]
22. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal serotype-specific IgG and opsonophagocytic activity in young Japanese patients with asplenia.
Takeshita K; Takeuchi N; Takahashi Y; Fukasawa C; Hishiki H; Hoshino T; Ishiwada N; Shimojo N
Hum Vaccin Immunother; 2021 Oct; 17(10):3687-3691. PubMed ID: 34213395
[TBL] [Abstract][Full Text] [Related]
24. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
[TBL] [Abstract][Full Text] [Related]
26. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).
Song JY; Chang CJ; Andrews C; Diez-Domingo J; Oh MD; Dagan R; Hartzel J; Pedley A; Li J; Sterling T; Tamms G; Chiarappa JA; Lutkiewicz J; Musey L; Tu Y; Buchwald UK;
Vaccine; 2021 Oct; 39(43):6422-6436. PubMed ID: 34489128
[TBL] [Abstract][Full Text] [Related]
27. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature.
Cripps AW; Folaranmi T; Johnson KD; Musey L; Niederman MS; Buchwald UK
Expert Rev Vaccines; 2021 Mar; 20(3):257-267. PubMed ID: 33567914
[No Abstract] [Full Text] [Related]
29. Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.
Romaru J; Bahuaud M; Lejeune G; Hentzien M; Berger JL; Robbins A; Lebrun D; N'Guyen Y; Bani-Sadr F; Batteux F; Servettaz A
Front Immunol; 2021; 12():791147. PubMed ID: 34987514
[TBL] [Abstract][Full Text] [Related]
30. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
32. Time interval of revaccination with 23-valent pneumococcal polysaccharide vaccine more than 5 years does not affect the immunogenicity and safety in the Japanese elderly.
Kawakami K; Kishino H; Kanazu S; Takahashi K; Iino T; Sawata M; Musey L
Hum Vaccin Immunother; 2018; 14(8):1931-1938. PubMed ID: 29580133
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
35. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
[No Abstract] [Full Text] [Related]
36. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.
Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Sinisalo M
Hum Vaccin Immunother; 2019; 15(12):2910-2913. PubMed ID: 31216225
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
[TBL] [Abstract][Full Text] [Related]
39. Pneumococcal conjugate vaccine-elicited antibody persistence and immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously vaccinated with 4 doses of either 7-valent or 13-valent pneumococcal conjugate vaccine.
Quinet B; Laudat F; Gurtman A; Patterson S; Sidhu M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2014 Oct; 33(10):1065-76. PubMed ID: 25093973
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
